Page last updated: 2024-11-02
pamidronate and Condition, Preneoplastic
pamidronate has been researched along with Condition, Preneoplastic in 1 studies
Research Excerpts
| Excerpt | Relevance | Reference |
|---|
| "Smoldering multiple myeloma (SMM) is usually followed expectantly without therapy." | 2.73 | Seven-year median time to progression with thalidomide for smoldering myeloma: partial response identifies subset requiring earlier salvage therapy for symptomatic disease. ( Alsayed, Y; Anaissie, E; Barlogie, B; Crowley, J; Epstein, J; Hoering, A; Hollmig, K; Jenkins, B; Kumar, NS; Petty, N; Pineda-Roman, M; Shaughnessy, JD; Srivastava, G; Szymonifka, J; van Rhee, F; Yaccoby, S; Zeldis, JB, 2008) |
Research
Studies (1)
| Timeframe | Studies, this research(%) | All Research% |
|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
Authors
| Authors | Studies |
|---|
| Barlogie, B | 1 |
| van Rhee, F | 1 |
| Shaughnessy, JD | 1 |
| Epstein, J | 1 |
| Yaccoby, S | 1 |
| Pineda-Roman, M | 1 |
| Hollmig, K | 1 |
| Alsayed, Y | 1 |
| Hoering, A | 1 |
| Szymonifka, J | 1 |
| Anaissie, E | 1 |
| Petty, N | 1 |
| Kumar, NS | 1 |
| Srivastava, G | 1 |
| Jenkins, B | 1 |
| Crowley, J | 1 |
| Zeldis, JB | 1 |
Clinical Trials (1)
Trial Overview
| Trial | Phase | Enrollment | Study Type | Start Date | Status |
|---|
| UARK 98-036, A Phase II Trial of Combination Bisphosphonate and Anti-Angiogenesis Therapy With Pamidronate and Thalidomide in Patients With Smoldering/Indolent Myeloma[NCT00083382] | Phase 2 | 83 participants (Actual) | Interventional | 1998-12-31 | Completed |
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Trial Outcomes
Best Response
"Best response to study treatment as defined by protocol-specific response criteria:~Complete Response (CR) = absence of urine and serum M-components by immunofixation; bone marrow should be adequately cellular (>20%) with <1% monoclonal plasma cells by DNA-clg flow cytometry; serum calcium level must be normal; no new bone lesions nor enlargement of existing lesions; Normalization of serum concentrations of normal immunoglobulins is not required for CR. Partial Response (PR) = Reduction by > 75% in serum myeloma protein production; Decrease in monoclonal marrow plasmacytosis to <5%; Decrease in Bence-Jones proteinuria by >90%; No new lytic bone lesions or soft tissue plasmacytoma.~Treatment Failures/Progressive Disease (PD) = Such patients do not fulfill the above criteria and/or have new lytic lesions (but not compression fractures), hypercalcemia, or other new manifestations of disease." (NCT00083382)
Timeframe: 2 years
| Intervention | participants (Number) |
|---|
| Treatment Failure/Progressive Disease | Partial Response | Complete Response |
|---|
| Thalidomide + Bisphosphonate | 56 | 17 | 10 |
Trials
1 trial available for pamidronate and Condition, Preneoplastic